Aura Biosciences

AURA

Market cap $376M

Overview Fund Activity

6.06 USD

-0.12

1.94%

At close Updated Sep 15, 12:26 PM EDT

1 day

-1.94%

5 days

-6.19%

1 month

-9.82%

3 months

-5.31%

6 months

-19.63%

Year to date

-26.63%

1 year

-39.22%

5 years

-59.05%

10 years

-59.05%

About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Employees: 106

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

37% more capital invested

Capital invested by funds: $232M [Q1] → $317M (+$85.3M) [Q2]

21.34% more ownership

Funds ownership: 79.35% [Q1] → 100.69% (+21.34%) [Q2]

11% more funds holding

Funds holding: 94 [Q1] → 104 (+10) [Q2]

10% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$22

263% upside

Avg. target

$22

263% upside

High target

$22

263% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Andres Y. Maldonado

$22

Buy

Reiterated

13 Aug 2025

See Analyst Rankings

Financial journalist opinion

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET.

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025.

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)

Aura Biosciences, Inc (NASDAQ:AURA ) Virtual Urologic Oncology Investor Event Conference Call March 24, 2025 4:30 PM ET Company Participants Jill Hopkins - Chief Medical Officer & President of R&D Sabine Brookman-May - Senior Vice President, Therapeutic Area Head Urologic Oncology Joseph McQuaid - Clinical Lead, Urologic Oncology Jennifer Linehan - St. John's Cancer Institute Neal Shore - Carolina Urologic Research Center Gary Steinberg - Professor, Department of Urology at Rush University in Chicago Conference Call Participants Andy Berens - Leerink Philip Nadeau - TD Cowen Oliver McCammon - LifeSci Capital Jon Wolleben - JMP Securities George Farmer - Scotiabank Operator Good afternoon, and welcome to the Aura Biosciences Virtual Urologic Oncology Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Aura website following the conclusion of the event.

Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

See News Rankings

Charts implemented using Lightweight Charts™